2018 Hepatic Encephalopathy Drug Development- Pipeline Analysis Report
With an estimated $5 billion market in the US alone, Hepatic Encephalopathy is a GI disorder affecting around 2 million people in the country. Hepatic Encephalopathy (HE) is a neuropsychiatric syndrome with serious health consequences where patients experience elevated and toxic ammonia levels (hyperammonemia). It occurs as a complication of acute or chronic liver disease.
Over 15 companies and universities are focusing on developing treatment options for Hepatic Encephaopathy.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Hepatic Encephaopathy pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Hepatic Encephaopathy pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Hepatic Encephaopathy pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Over 15 companies and universities are focusing on developing treatment options for Hepatic Encephaopathy.
To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Hepatic Encephaopathy pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Hepatic Encephaopathy pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Hepatic Encephaopathy pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of Figures
1.2 List of Tables
2 HEPATIC ENCEPHALOPATHY PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Hepatic Encephalopathy Pipeline Snapshot
2.3 Hepatic Encephalopathy Pipeline by Phase
2.4 Hepatic Encephalopathy Pipeline by Company
2.5 Hepatic Encephalopathy Pipeline by Mechanism of Action
3 HEPATIC ENCEPHALOPATHY- COMPANY WISE PIPELINE ANALYSIS
Cosmo Pharmaceuticals NV
KannaLife Sciences
Mallinckrodt Pharmaceuticals
Rebiotix Inc
Romark Laboratories
Synlogic Inc
Umecrine Cognition AB
4 HEPATIC ENCEPHALOPATHY R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN HEPATIC ENCEPHALOPATHY PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of Figures
1.2 List of Tables
2 HEPATIC ENCEPHALOPATHY PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Hepatic Encephalopathy Pipeline Snapshot
2.3 Hepatic Encephalopathy Pipeline by Phase
2.4 Hepatic Encephalopathy Pipeline by Company
2.5 Hepatic Encephalopathy Pipeline by Mechanism of Action
3 HEPATIC ENCEPHALOPATHY- COMPANY WISE PIPELINE ANALYSIS
Cosmo Pharmaceuticals NV
KannaLife Sciences
Mallinckrodt Pharmaceuticals
Rebiotix Inc
Romark Laboratories
Synlogic Inc
Umecrine Cognition AB
4 HEPATIC ENCEPHALOPATHY R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN HEPATIC ENCEPHALOPATHY PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Hepatic Encephalopathy Pipeline by Phase, H1- 2018
Figure 2: Hepatic Encephalopathy Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Hepatic Encephalopathy Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
Figure 1: Hepatic Encephalopathy Pipeline by Phase, H1- 2018
Figure 2: Hepatic Encephalopathy Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Hepatic Encephalopathy Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018
LIST OF TABLES
Table 1: Hepatic Encephalopathy Pipeline by Phase, H1- 2018
Table 2: Hepatic Encephalopathy Pipeline by Companies, H1- 2018
Table 3: Hepatic Encephalopathy Pipeline by Mechanism of Action, H1- 2018
Table 4: Cosmo Pharmaceuticals NV Hepatic Encephalopathy Pipeline, May 2018
Table 5: KannaLife Sciences Hepatic Encephalopathy Pipeline, May 2018
Table 6: Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Pipeline, May 2018
Table 7: Rebiotix Inc Hepatic Encephalopathy Pipeline, May 2018
Table 8: Romark Laboratories Hepatic Encephalopathy Pipeline, May 2018
Table 9: Synlogic Inc Hepatic Encephalopathy Pipeline, May 2018
Table 10: Umecrine Cognition AB Hepatic Encephalopathy Pipeline, May 2018
Table 1: Hepatic Encephalopathy Pipeline by Phase, H1- 2018
Table 2: Hepatic Encephalopathy Pipeline by Companies, H1- 2018
Table 3: Hepatic Encephalopathy Pipeline by Mechanism of Action, H1- 2018
Table 4: Cosmo Pharmaceuticals NV Hepatic Encephalopathy Pipeline, May 2018
Table 5: KannaLife Sciences Hepatic Encephalopathy Pipeline, May 2018
Table 6: Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Pipeline, May 2018
Table 7: Rebiotix Inc Hepatic Encephalopathy Pipeline, May 2018
Table 8: Romark Laboratories Hepatic Encephalopathy Pipeline, May 2018
Table 9: Synlogic Inc Hepatic Encephalopathy Pipeline, May 2018
Table 10: Umecrine Cognition AB Hepatic Encephalopathy Pipeline, May 2018
